App-Quantinova.ai

Is primary writing tremor a form fruste of dystonia?

A. Latorre - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Is repetitive transcranial magnetic stimulation an effective tool to treat pain in Parkinson’s Disease?

M. Bonello - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

N. Malek - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Levodopa

Long-term effects of music as an auditory cue on motor and non-motor symptoms of Parkinson’s disease: A case report

F. Lindop - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Longitudinal observational study on late onset Parkinson’s disease over a decade

S. Raha - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Midbrain Diameter Measurements on High-Resolution Computer Tomography Scans to aid diagnosis of Progressive Supranuclear Palsy

S. Potluri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Motivational effects on action selection and memory

S. Hirschbichler - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Multimorbidity predicts quality of life but not motor severity in early Parkinson’s disease

R. Gravell - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington’s disease

L. Byrne - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Neuromelanin-MRI in REM sleep behaviour disorder predicts dopaminergic dysfunction and clinical risk of Parkinson’s disease

T. Barber - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Neuropathology of dopa-responsive dystonia due to Tyrosine hydroxylase deficiency

S. Schreglmann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Segawa syndrome autosomal recessive

L-Tyrosine

Non-invasive, automated corneal nerve quantification reveals neurodegeneration in Parkinson’s disease: A potential novel imaging biomarker

S. Lim - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Parkinson's disease

N/A

Non-Motor Symptom In Young Onset Parkinson Disease as a Cause of Pharmacoresistence In Epilepsy

M. Awadh - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Levetiracetam

Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

K. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Orthostatic hypotension

Levodopa

Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease

L. Byrne - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Phase-locked transcranial alternating current stimulation of the cerebellum for essential tremor

S. Schreglmann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Essential tremor

N/A

Probable MSA presenting initially with urinary retention

S. Simeoni - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Male Sexual Dysfunction

N/A

Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia

E. Pioli - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Amantadine

Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

K. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Carbidopa and Levodopa

Referral and diagnostic time intervals from symptom onset to death in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Parkinson’s disease (PD)

D. Swallow - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

N/A

Filters

45280 Abstracts